Sylatron Interactions
There are 228 drugs known to interact with Sylatron (peginterferon alfa-2b), along with 20 disease interactions. Of the total drug interactions, 41 are major, 183 are moderate, and 4 are minor.
- View all 228 medications that may interact with Sylatron
- View Sylatron disease interactions (20)
Most frequently checked interactions
View interaction reports for Sylatron (peginterferon alfa-2b) and the medicines listed below.
- Astelin (azelastine nasal)
- Astelin (azelastine nasal)
- Calcium 600 D (calcium / vitamin d)
- Calcium 600 D (calcium / vitamin d)
- CoQ10 (ubiquinone)
- CoQ10 (ubiquinone)
- Effexor XR (venlafaxine)
- Effexor XR (venlafaxine)
- Fish Oil (omega-3 polyunsaturated fatty acids)
- Fish Oil (omega-3 polyunsaturated fatty acids)
- Flonase (fluticasone nasal)
- Flonase (fluticasone nasal)
- Klonopin (clonazepam)
- Klonopin (clonazepam)
- Lopid (gemfibrozil)
- Lopid (gemfibrozil)
- multivitamin
- multivitamin
- Synthroid (levothyroxine)
- Synthroid (levothyroxine)
- Valium (diazepam)
- Valium (diazepam)
- Vytorin (ezetimibe / simvastatin)
- Vytorin (ezetimibe / simvastatin)
- Vyvanse (lisdexamfetamine)
- Vyvanse (lisdexamfetamine)
- Zyrtec (cetirizine)
- Zyrtec (cetirizine)
Sylatron disease interactions
There are 20 disease interactions with Sylatron (peginterferon alfa-2b) which include:
- renal dysfunction
- autoimmune diseases
- cardiac disease
- CNS dysfunction
- depression
- thyroid dysfunction
- autoimmune hepatitis
- depression
- severe hepatic disease
- hemoglobinopathies
- renal dysfunction
- colitis
- diabetes mellitus
- myelosuppression
- peripheral neuropathy
- bone marrow suppression
- endocrine disorders
- ophthalmological disorders
- pancreatitis
- pulmonary disorders
Report options
More about Sylatron (peginterferon alfa-2b)
- Sylatron consumer information
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antineoplastic interferons
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Tecentriq
Tecentriq (atezolizumab) is a monoclonal antibody used to treat non-small cell lung cancer, small ...
Yervoy
Yervoy (ipilimumab) is a cancer treatment used for lung cancer, melanoma, renal cell carcinoma ...
Tafinlar
Tafinlar is a prescription medicine used to treat BRAF mutated melanoma, non-small cell lung ...
Braftovi
Braftovi is a targeted cancer treatment used in combination with Mektovi, mFOLFOX6, or Erbitux, to ...
Opdualag
Opdualag (nivolumab and relatlimab-rmbw) is used for the treatment of unresectable or metastatic ...
Interferon alfa-2b
Interferon alfa-2b systemic is used for angioblastoma, condylomata acuminata, conjunctival ...
Dacarbazine
Dacarbazine systemic is used for hodgkin's lymphoma, melanoma, melanoma, metastatic
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.